Bifogade filer
PDF
Kurs & Likviditet
Beskrivning
| Land | Danmark |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Hørsholm, Denmark, April 19, 2022 - ExpreS2ion Biotech Holding AB's affiliate ExpreS2ion Biotechnologies ApS ("ExpreS2ion") announces that Frontiers in Immunology published an article about the high level of antibodies induced by the ABNCoV2 COVID-19 vaccine in non-human primates.
Excerpt: "In summary, ABNCoV2 induced strong and long-lasting neutralizing antibody responses and efficacy against SARS-CoV-2 in NHP (non-human primates). Together with the comparable variant neutralization capacity seen in the serum of vaccinated animals, these data may indicate a potential for broad protection afforded by the ABNCoV2 vaccine."
The scientific article is entitled "A Capsid Virus-Like Particle-Based SARS-CoV-2 Vaccine Induces High Levels of Antibodies and Protects Rhesus Macaques". Paper reference: Volkmann et al., Front. Immunol. (2022) https://doi.org/10.3389/fimmu.2022.857440. The article can also be found via this link (https://www.frontiersin.org/articles/10.3389/fimmu.2022.857440/full), as well as via the Research Publications (https://expres2ionbio.com/newspublications/research-publications/) page of ExpreS[2]ion's website.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
Telefon: +46 11 32 30 732
E-post: ca@skmg.se